Biologics - STAT

Pharmalot By Ed Silverman

Will the ‘patent dance’ cause Amgen to temporarily pull a biosimilar off the market?

Biotech By Elizabeth Cooney

Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it

First Opinion By Sean McGowan

Five years on, biosimilars need support from all health care players

First Opinion By Leah Christl

From bench to bedside, biologics require excellence at every stage

A magnified view of C. difficile bacteria.

Biotech By Kate Sheridan

Microbiome-based drugs likely to face FDA’s biologics pathway

Politics By Erin Mershon

Drug makers jostle over potential Medicare changes in congressional spending deal

Business By Associated Press

Samsung’s biotech unit debuts in Seoul. Here’s what to know

In the Lab By Eric Boodman

Freeze-dried drug factories could make a slew of medicines — just add water

Pharmalot By Ed Silverman

Biosimilar names may affect pharmacist dispensing habits

Pharmalot By Ed Silverman

Some biosimilars are just as good as some pricey biologics

Pharmalot By Ed Silverman

Court ruling on biosimilar launches could increase health care costs

Pharmalot By Ed Silverman

Bill introduced to speed cheaper versions of pricey biologics to market

Pharmalot By Ed Silverman

Supreme Court asks Obama administration for views on biosimilar rules

Pharmalot By Ed Silverman

Unintended twist in Obamacare may cost some Medicare patients more for biosimilars

Pharmalot By Ed Silverman

Most Read

Biologics lose protection as U.S.-Canada-Mexico trade agreement moves forward

U.S. biologics and biosimilars need distinguishable names

Lawmakers slip a win for pharma into federal spending package

Trade agreement drug monopoly is obsolete given faster, better drug discovery

Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own

Biosimilar approval and adoption in the U.S. needs to be expedited

Teva, one of the biggest generic makers, joins the brand-name club

Biosimilars: the cure for sky-high drug prices or a stake in the heart of innovation?

All Coverage

Will the ‘patent dance’ cause Amgen to temporarily pull a biosimilar off the market?

Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it

Five years on, biosimilars need support from all health care players

From bench to bedside, biologics require excellence at every stage

Microbiome-based drugs likely to face FDA’s biologics pathway

Drug makers jostle over potential Medicare changes in congressional spending deal

Samsung’s biotech unit debuts in Seoul. Here’s what to know

Freeze-dried drug factories could make a slew of medicines — just add water

Biosimilar names may affect pharmacist dispensing habits

Some biosimilars are just as good as some pricey biologics

Court ruling on biosimilar launches could increase health care costs

Bill introduced to speed cheaper versions of pricey biologics to market

Supreme Court asks Obama administration for views on biosimilar rules

Unintended twist in Obamacare may cost some Medicare patients more for biosimilars

FDA proposes biosimilar labeling that favors generic drug makers